Literature DB >> 23425431

Nanotechnology in corneal neovascularization therapy--a review.

Lilian Gonzalez1, Raymond J Loza, Kyu-Yeon Han, Suhair Sunoqrot, Christy Cunningham, Patryk Purta, James Drake, Sandeep Jain, Seungpyo Hong, Jin-Hong Chang.   

Abstract

Nanotechnology is an up-and-coming branch of science that studies and designs materials with at least one dimension sized from 1-100 nm. These nanomaterials have unique functions at the cellular, atomic, and molecular levels. The term "nanotechnology" was first coined in 1974. Since then, it has evolved dramatically and now consists of distinct and independent scientific fields. Nanotechnology is a highly studied topic of interest, as nanoparticles can be applied to various fields ranging from medicine and pharmacology, to chemistry and agriculture, to environmental science and consumer goods. The rapidly evolving field of nanomedicine incorporates nanotechnology with medical applications, seeking to give rise to new diagnostic means, treatments, and tools. Over the past two decades, numerous studies that underscore the successful fusion of nanotechnology with novel medical applications have emerged. This has given rise to promising new therapies for a variety of diseases, especially cancer. It is becoming abundantly clear that nanotechnology has found a place in the medical field by providing new and more efficient ways to deliver treatment. Ophthalmology can also stand to benefit significantly from the advances in nanotechnology research. As it relates to the eye, research in the nanomedicine field has been particularly focused on developing various treatments to prevent and/or reduce corneal neovascularization among other ophthalmologic disorders. This review article aims to provide an overview of corneal neovascularization, currently available treatments, and where nanotechnology comes into play.

Entities:  

Mesh:

Year:  2013        PMID: 23425431      PMCID: PMC3601629          DOI: 10.1089/jop.2012.0158

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  88 in total

1.  Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.

Authors:  Claudia Di Tommaso; Jean-Louis Bourges; Fatemeh Valamanesh; Gregory Trubitsyn; Alicia Torriglia; Jean-Claude Jeanny; Francine Behar-Cohen; Robert Gurny; Michael Möller
Journal:  Eur J Pharm Biopharm       Date:  2012-03-16       Impact factor: 5.571

2.  Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.

Authors:  Veysi Öner; Cem Küçükerdönmez; Yonca Aydın Akova; Aysel Çolak; Aylin Karalezli
Journal:  Ophthalmic Res       Date:  2012-04-24       Impact factor: 2.892

Review 3.  Corneal changes in ectrodactyly-ectodermal dysplasia-cleft lip and palate syndrome: case series and literature review.

Authors:  Anthony F Felipe; Azin Abazari; Kristin M Hammersmith; Christopher J Rapuano; Parveen K Nagra; Baltasar Moratal Peiro
Journal:  Int Ophthalmol       Date:  2012-05-23       Impact factor: 2.031

Review 4.  Nanotechnology in ocular delivery: current and future directions.

Authors:  Yasmin Sultana; D P Maurya; Z Iqbal; M Aqil
Journal:  Drugs Today (Barc)       Date:  2011-06       Impact factor: 2.245

Review 5.  Treatments for corneal neovascularization: a review.

Authors:  Deepak Gupta; Chris Illingworth
Journal:  Cornea       Date:  2011-08       Impact factor: 2.651

6.  Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty.

Authors:  C Cursiefen; H Wenkel; P Martus; A Langenbucher; N X Nguyen; B Seitz; M Küchle; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

7.  Rapid ocular angiogenic control via naked DNA delivery to cornea.

Authors:  S U Stechschulte; A M Joussen; H A von Recum; V Poulaki; Y Moromizato; J Yuan; R J D'Amato; C Kuo; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-08       Impact factor: 4.799

8.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Authors:  Felix Bock; Yanyan König; Friedrich Kruse; Martin Baier; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-13       Impact factor: 3.117

9.  Target drug delivery system as a new scarring modulation after glaucoma filtration surgery.

Authors:  Tingting Shao; Xiaoning Li; Jian Ge
Journal:  Diagn Pathol       Date:  2011-07-08       Impact factor: 2.644

10.  Nanotechnology in medicine and relevance to dermatology: present concepts.

Authors:  K H Basavaraj
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

View more
  15 in total

1.  Curcumin nanoparticles inhibit corneal neovascularization.

Authors:  Nirparaj Pradhan; Rajdeep Guha; Sushovan Chowdhury; Sudip Nandi; Aditya Konar; Sarbani Hazra
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

2.  Acute corneal injury in rabbits following nitrogen mustard ocular exposure.

Authors:  Dinesh G Goswami; Rama Kant; David A Ammar; Dileep Kumar; Robert W Enzenauer; J Mark Petrash; Neera Tewari-Singh; Rajesh Agarwal
Journal:  Exp Mol Pathol       Date:  2019-06-21       Impact factor: 3.362

3.  Serial optical coherence tomography angiography for corneal vascularization.

Authors:  Yijun Cai; Jorge L Alio Del Barrio; Mark R Wilkins; Marcus Ang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-08       Impact factor: 3.117

Review 4.  Nanoparticles and nanofibers for topical drug delivery.

Authors:  Ritu Goyal; Lauren K Macri; Hilton M Kaplan; Joachim Kohn
Journal:  J Control Release       Date:  2015-10-28       Impact factor: 9.776

5.  Anti-angiogenic effect of hexahydrocurcumin in rat corneal neovascularization.

Authors:  Chien-Neng Kuo; Ching-Hsein Chen; San-Ni Chen; Jou-Cheng Huang; Li-Ju Lai; Chien-Hsiung Lai; Chia-Hui Hung; Chien-Hsing Lee; Chung-Yi Chen
Journal:  Int Ophthalmol       Date:  2017-04-09       Impact factor: 2.031

Review 6.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

7.  Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.

Authors:  Lisa R Schopf; Alexey M Popov; Elizabeth M Enlow; James L Bourassa; Winston Z Ong; Pawel Nowak; Hongming Chen
Journal:  Transl Vis Sci Technol       Date:  2015-06-11       Impact factor: 3.283

8.  Effect of dexamethasone treatment at variable therapeutic windows in reversing nitrogen mustard-induced corneal injuries in rabbit ocular in vivo model.

Authors:  Dinesh G Goswami; Neha Mishra; Rama Kant; Chapla Agarwal; David A Ammar; J Mark Petrash; Neera Tewari-Singh; Rajesh Agarwal
Journal:  Toxicol Appl Pharmacol       Date:  2022-01-30       Impact factor: 4.219

9.  Multifunctional nanotherapeutics for treatment of ocular disease.

Authors:  Tian Xia
Journal:  Ann Eye Sci       Date:  2017-04-28

10.  Comparison Therapeutic Effects of Ciprofloxacin, Silver Nanoparticles and Their Combination in the Treatment of Pseudomonas keratitis in Rabbit: An Experimental Study.

Authors:  Mohammad Zavarshani; Malahat Ahmadi; Habib Dastmalchi Saei; Ali Asghar Tehrani; Bahram Dalir Naghadeh
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.